HomeCompareHLUYY vs JEPQ

HLUYY vs JEPQ: Dividend Comparison 2026

HLUYY yields 21.52% · JEPQ yields 11.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HLUYY wins by $35.3K in total portfolio value
10 years
HLUYY
HLUYY
● Live price
21.52%
Share price
$22.00
Annual div
$4.73
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.1K
Annual income
$7,902.94
Full HLUYY calculator →
JEPQ
JPMorgan Nasdaq Equity Premium Income ETF
● Live price
11.10%
Share price
$55.52
Annual div
$6.16
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.8K
Annual income
$2,152.59
Full JEPQ calculator →

Portfolio growth — HLUYY vs JEPQ

📍 HLUYY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHLUYYJEPQ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HLUYY + JEPQ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HLUYY pays
JEPQ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HLUYY
Annual income on $10K today (after 15% tax)
$1,829.43/yr
After 10yr DRIP, annual income (after tax)
$6,717.50/yr
JEPQ
Annual income on $10K today (after 15% tax)
$943.83/yr
After 10yr DRIP, annual income (after tax)
$1,829.70/yr
At 15% tax rate, HLUYY beats the other by $4,887.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HLUYY + JEPQ for your $10,000?

HLUYY: 50%JEPQ: 50%
100% JEPQ50/50100% HLUYY
Portfolio after 10yr
$62.5K
Annual income
$5,027.76/yr
Blended yield
8.05%
📊

Analyst Conviction Gap

Where Wall Street is split right now

HLUYY
Analyst Ratings
1
Hold
Consensus: Hold
JEPQ
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HLUYY buys
0
JEPQ buys
0
No recent congressional trades found for HLUYY or JEPQ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHLUYYJEPQ
Forward yield21.52%11.10%
Annual dividend / share$4.73$6.16
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$80.1K$44.8K
Annual income after 10y$7,902.94$2,152.59
Total dividends collected$47.3K$16.3K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: HLUYY vs JEPQ ($10,000, DRIP)

YearHLUYY PortfolioHLUYY Income/yrJEPQ PortfolioJEPQ Income/yrGap
1← crossover$12,852$2,152.27$11,930$1,110.39+$922.00HLUYY
2$16,337$2,585.20$14,133$1,224.34+$2.2KHLUYY
3$20,552$3,071.18$16,632$1,340.46+$3.9KHLUYY
4$25,601$3,610.76$19,454$1,457.97+$6.1KHLUYY
5$31,597$4,203.63$22,626$1,576.08+$9.0KHLUYY
6$38,657$4,848.69$26,175$1,694.09+$12.5KHLUYY
7$46,908$5,544.07$30,133$1,811.32+$16.8KHLUYY
8$56,478$6,287.15$34,531$1,927.17+$21.9KHLUYY
9$67,506$7,074.71$39,403$2,041.08+$28.1KHLUYY
10$80,135$7,902.94$44,787$2,152.59+$35.3KHLUYY

HLUYY vs JEPQ: Complete Analysis 2026

HLUYYStock

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.

Full HLUYY Calculator →

JEPQETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →
📬

Get this HLUYY vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HLUYY vs SCHDHLUYY vs JEPIHLUYY vs OHLUYY vs KOHLUYY vs MAINHLUYY vs XYLDHLUYY vs QYLDHLUYY vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.